

Programme

The TOPRA 45th Spring Introductory Course: Introduction to Pharmaceutical Regulatory Affairs

28-31 March 2023

Coppid Beech Hotel, Bracknell, Berkshire, UK

Day 1

28 March 2023 Chairperson: Morning: Claire Beggs, Jazz Pharma, Afternoon: Zena Smith, Jazz Pharma Day Co-ordinator: Dima Al-Hadithi, Minaret Consulting Limited **All timings presented are BST

08:00 Registration

- 08:30 Welcome & Introduction to the course Claire Beggs, Jazz Pharma
- 08:45 New Product Development, The European Regulatory Environment & the Role of Regulatory Affairs Steve Brookes, *Biogen*
- 09:45 **Overview of the MAA** Jenny Lamport, *1st Regulatory Ltd.*
- 10:45 Break
- 11.00 Chemical Development/Quality Brian Corrigan, MSD

12:00 Lunch

- 12:45 **Pharmaceutical Development/Quality** *Brian Corrigan, MSD*
- 13:45Module 3. An Agency PerspectiveMirza Ćatibušić, Health Products Regulatory Authority (HPRA)
- 14:45Panel Q&A and Closing RemarksZena, Smith, Jazz Pharma, Claire Beggs, Chair
- 15:00 Case Study 1 Introduction and break
- 15:30 Case Study 1. Chemistry & Pharmacy Zena Smith, *Jazz Pharma*
- 17:00 End of day 1
- 19:00 **Dinner**

Day 2

29 March 2023 Chairperson: Xavier Luria, DDR Consultancy Day Co-ordinator: Bob Ibbotson, Shionogi BV

****All timings presented are BST**

08:30	Understanding the Need for Non-Clinical Safety Studies Chris Powell, Cambridge Consulting
09:30	The Importance of Pharmacokinetics & Pharmacodynamics in Drug Development Helen Walker, HW ClinPharm Ltd
10:30	Tea/ coffee break
10:45	The Components of the Non-Clinical Section of a Marketing Authorisation Application David Jones, <i>Consultant</i>
11:35	Non-Clinical Panel Discussion and Questions
12:00	Clinical Drug Development, Paediatric Investigation Plans & the link with Regulatory Affairs Steve Pinder, Envestia Ltd
13:00	Lunch
13:45	The Regulation of Clinical Trials in Europe – An Agency Perspective Gunilla Andrew Nielsen, MPA
14:40	The European Clinical Trials Process – Industry Perspective Shaila Choi, Seagen Ltd
15:15	Tea/Coffee Break
15:25	The MAA – the perspective of an EU Regulatory Authority Clinical Assessor Jan Span, <i>Medicines Evaluation Board (MEB)</i>
16:10	Clinical Panel Discussion and Questions
16:30	Case Study 2. Non-Clinical & Clinical Development Ming Ewe, Smarter Biotech Solutions Limited
18:30	End of day 2

19:00 **Dinner**

Day 3

30 March 2023 Chairperson: Niamh Lawler Turner, University of Limerick Day Co-ordinator: Ming Ewe, Smarter Biotech Solutions Limited **All timings presented are BST

08:45	The Centralised Proce	edure – Practica	l Industry	Experience
-------	-----------------------	------------------	------------	------------

Will James, Pfizer

- 09:45 The Mutual Recognition Procedure & the Decentralised Procedure Practical Industry Experience Stephen Thompson, *S-Cubed*
- 10:45 Break
- 11:00 Generics Andrew Modley, *Teva*
- 12:00 Lunch

13:00 **Regulatory Strategy Session Part 1:**

- 1. Initial considerations for Strategic Thinking
- 2. Think Global Key considerations for Worldwide Markets
- 3. Regulatory/HTA Advice
- 4. Paediatric Development and PIPs

David Kane, Vertex / Neil Roberts, Gilead

14:15 Break

14:30 **Regulatory Strategy Session Part 2:**

- 5. Orphan Disease Considerations
- 6. Accelerating Access (Expedited Pathways)
- 7. Tradename
- 8. IP and Exclusivity Considerations

David Kane, Vertex / Neil Roberts, Gilead

- 15:45Closing remarks of the dayNiamh Lawler-Turner, University of Limerick
- 16:00 Case Study 3. Regulatory Strategy David Kane, Vertex
- 17:30 End of day 3
- 19:00 **Dinner**

Day 4 31 Mar 2023 Chairperson: Gwenaelle Pemberton, *Syncona Ltd* Day Co-ordinator: Susanna Dean, *Apothecom Ltd* **All timings presented are BST

08:30	Opening and learning objectives presentation Gwenaelle Pemberton, <i>Syncona Ltd</i>
08:40	Lifecycle Management – Quality Richard Keane, <i>Biogen Idec Ltd.</i>
09.40	Lifecycle Management – Safety & Efficacy Kay Martin, <i>Biogen</i>
10:40	Break
10:55	Product Information – Regulation of the SmPC, PIL & label Julia Coombes, MHRA
12:10	Q&A session Panel: Richard Keane, Kay Martin, Julia Coombes
12:30	Lunch
13:15	Case Study 4: Variations Jenny Davies, <i>Haleon</i>
14:30	Break
14:45	Health Technology Assessment: Why and where does the regulatory professional become involved? Sara Lopes, Shionogi BV
15:15	An Introduction to Biotechnology & Advanced Therapy Medicinal Products Paul Smith, MetisRA Consulting Ltd
16:15	The Future ahead in Regulatory Affairs: What to expect next Laura Liebers, Vertex Pharmaceuticals
16:45	Closing remarks Gwenaelle Pemberton

17:00 End of day 4